[Effect of streptodecase and heparin on the state of hemostasis in patients with acute myocardial infarction].
The article deals with the effect of the intravenous administration of streptodekase with heparin on the hemostatic system in patients with acute myocardial infarction. The data obtained are compared with the corresponding parameters in patients treated with native streptokinase. The advantages of the new thrombolytic drug over ordinary streptokinase are shown: a one-time administration of the whole therapeutic dose of streptodekase allows a significant simplification of the thrombolytic therapy scheme; streptodekase induces prolonged activation of fibrinolysis (up to 5-7 days) without any signs of its subsequent depression and with the minimum inhibition of blood coagulation. The specific selective influence of streptodekase on the fibrinolytic system helps to obviate hemorrhagic and thromboembolic complications characteristic of native streptokinase. In addition, low antigenicity and toxicity of streptodekase ensure the absence of any allergic and adverse side-effects in patients treated with the drug.
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D013300:Streptokinase / Q000008:administration & dosage*
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D005340:Fibrinogen; D006493:Heparin; D013300:Streptokinase
Vliianie streptodekazy s geparinom na sostoianie gemostaza u bol'nykh ostrym infarktom miokarda.